The Guardian/Kenan Malik: Big pharma can only see the benefit of R&D for wealthy markets

The Guardian ericas
   
Opinion
Big pharma can only see the benefit of R&D for wealthy markets
Kenan Malik
Kenan Malik

There is too little incentive for pharmaceutical companies to work on treatments for diseases of low-income countries

Sun 5 May 2019 06.00 BST

Shares
26
A nurse prepares to give the malaria vaccine to a baby in Ghana.

At the end of April, health workers in Malawi, Ghana and Kenya began rolling out the first and so far only vaccine proved to protect against malaria. It’s part of a World Health Organization pilot programme that could immunise more than one million children by 2023. Yet, while this is a welcome step in the fight against malaria, it also exposes the problems in developing vaccines for use in non-western countries.

    This kind of endeavour can’t be repeated, from GSK’s point of view
    GlaxoSmithKline

The vaccine, called RTS,S, prevents malaria in only 40% of cases. It has taken more than 30 years to develop and cost more than $700m. The manufacturer, GlaxoSmithKline, proclaimed itself “incredibly proud to see it rolled out”, but added: “This kind of endeavour can’t be repeated, from GSK’s point of view.” That’s because all drug research and development is based on a model of a multinational charging high prices for products tailored to wealthy markets. As there is little incentive for pharmaceutical companies to conduct R&D for diseases that affect populations with limited purchasing power, a report for Oxfam and Médecins Sans Frontières observes, so “some diseases continue to be unaddressed by vaccines altogether, while many vaccines are not well-adapted for people in developing countries”.

There are about 240 vaccines in early stages of development for diseases that predominantly affect people in non-western countries. Yet only a handful have in recent years made it through the pipeline for use in low-income countries. It’s an indictment of a system in which profit talks but needs are neglected.

• Kenan Malik is an Observer columnist
Topics

    Malaria
    Opinion

    Pharmaceuticals industry
    World Health Organization
    Africa
    Global health
    GlaxoSmithKline
    Drugs
    comment

    Share on LinkedIn
    Share on Pinterest
    Share on WhatsApp
    Share on Messenger

Most popular

    World
    Europe
    US
    Americas
    Asia
    Australia
    Middle East
    Africa
    Inequality
    Cities
    Global development

    Contact us
    Complaints & corrections
    SecureDrop
    Work for us
    Privacy policy
    Cookie policy
    Terms & conditions
    Help

    All topics
    All writers
    Digital newspaper archive
    Facebook
    Twitter

    Advertise with us
    Search UK jobs
    Dating
    Discount Codes

Support The Guardian
Available for everyone, funded by readers
Contribute
Subscribe
Back to top
© 2019 Guardian News & Media Limited or its affiliated companies. All rights reserved.






Sent from Samsung tablet.